Loading...
XSHG688098
Market cap303mUSD
Dec 25, Last price  
5.39CNY
1D
-4.26%
1Q
34.08%
IPO
-79.89%
Name

Shanghai Shen Lian Biomedical Corp

Chart & Performance

D1W1MN
XSHG:688098 chart
P/E
70.22
P/S
7.34
EPS
0.08
Div Yield, %
1.48%
Shrs. gr., 5y
3.18%
Rev. gr., 5y
1.85%
Revenues
301m
-8.25%
193,093,762203,652,967240,922,685267,705,441302,075,997275,137,414253,809,330337,732,400358,429,248328,594,513301,487,059
Net income
32m
-48.42%
41,823,38561,140,41075,843,83573,471,83998,677,95487,580,33277,957,157129,514,301110,201,86261,101,43631,518,678
CFO
4m
-61.21%
51,788,300105,978,10030,862,50047,995,28774,605,137121,129,68253,812,891111,730,33890,119,9839,088,1883,525,531
Dividend
Jun 14, 20240.035 CNY/sh
Earnings
May 16, 2025

Profile

Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.
URL
http://www.slbio.com.cn/
IPO date
Oct 28, 2019
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
301,487
-8.25%
328,595
-8.32%
358,429
6.13%
Cost of revenue
242,392
221,254
213,164
Unusual Expense (Income)
NOPBT
59,095
107,341
145,265
NOPBT Margin
19.60%
32.67%
40.53%
Operating Taxes
6,415
13,580
21,521
Tax Rate
10.85%
12.65%
14.82%
NOPAT
52,680
93,761
123,744
Net income
31,519
-48.42%
61,101
-44.55%
110,202
-14.91%
Dividends
(32,774)
(36,958)
(40,970)
Dividend yield
1.11%
1.13%
0.90%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
334
136
132
Long-term debt
1,834
620
764
Deferred revenue
9,488
10,364
11,299
Other long-term liabilities
1
1
1
Net debt
(44,393)
(357,109)
(467,394)
Cash flow
Cash from operating activities
3,526
9,088
90,120
CAPEX
(129,632)
Cash from investing activities
21,864
36,009
Cash from financing activities
(33,142)
FCF
(62,415)
(13,129)
(52,765)
Balance
Cash
207,351
357,865
468,290
Long term investments
(160,790)
Excess cash
31,487
341,435
450,369
Stockholders' equity
978,332
968,138
950,141
Invested Capital
1,486,320
1,153,136
1,025,742
ROIC
3.99%
8.61%
13.29%
ROCE
3.89%
7.18%
9.84%
EV
Common stock shares outstanding
393,983
410,644
410,644
Price
7.48
-5.79%
7.94
-28.08%
11.04
-31.39%
Market cap
2,946,996
-9.62%
3,260,513
-28.08%
4,533,510
-32.56%
EV
2,920,939
2,903,404
4,066,116
EBITDA
122,546
164,409
189,007
EV/EBITDA
23.84
17.66
21.51
Interest
36
12,677
21
Interest/NOPBT
0.06%
11.81%
0.01%